Tucatinib Shows Efficacy in Delaying HER2-Positive Breast Cancer Brain Metastasis

A national clinical trial led by Duke University researchers found that adding tucatinib to standard care substantially delayed HER2-positive breast cancer progression to the brain. Over half of 47 patients had no worsening of brain metastasis after 19.6 months, with encouraging overall survival. These results, presented at ESMO, could prompt immediate changes in standard of care since tucatinib is already available.